Morgan Stanley upgrades UCB stock rating on Bimzelx sales outlook

Morgan Stanley upgraded UCB SA to Overweight from Equalweight, raising its price target to EUR220, citing the Belgian pharmaceutical company's robust financial health and a projected 22% EBITDA CAGR from 2025-2028, significantly outpacing sector peers. This upgrade reflects increased peak sales estimates for Bimzelx and greater pipeline optionality, justifying UCB's current 33% premium valuation despite U.S. policy risks, with potential for 40% valuation upside. Concurrently, TD Cowen reiterated its Buy rating and EUR250 price target, reinforced by positive physician feedback on Bimzelx's potential in Hidradenitis Suppurativa, contributing to a projected peak sales exceeding EUR6 billion.

Analysis

UCB SA has received two significant positive analyst updates, signaling strong institutional confidence in its growth trajectory. Morgan Stanley upgraded the stock to Overweight with a EUR220 price target, citing a superior top-line growth outlook, forecasting an approximate 22% EBITDA CAGR for 2025-2028, which is more than double the 10% expected for sector peers. This growth forecast, supported by a perfect Piotroski Score of 9 indicating robust financial health, is used to justify UCB's premium valuation of roughly 16x FY’25 EV/EBITDA, a 33% premium to specialty pharma peers. Concurrently, TD Cowen reiterated its Buy rating and a more aggressive EUR250 price target, based on positive physician and payor feedback from a recent healthcare conference. Both investment banks anchor their theses on the blockbuster potential of the drug Bimzelx, with Morgan Stanley raising its price target due to increased peak sales estimates and TD Cowen projecting peak sales to exceed EUR6 billion, with over EUR3 billion from the Hidradenitis Suppurativa (HS) indication alone. While U.S. policy is noted as a sector-wide risk, the consensus points to UCB's clear earnings visibility and pipeline strength as key differentiators, with Morgan Stanley suggesting a potential 40% valuation upside contingent on continued positive earnings revisions.

Key Decisions for Investors

• Consider the consensus bullish outlook from two separate investment banks, which is underpinned by a projected 22% EBITDA CAGR from 2025-2028, significantly outpacing the specialty pharma sector.
• The investment thesis is heavily concentrated on the commercial success of Bimzelx; investors should closely monitor its launch and adoption progress, particularly in the Hidradenitis Suppurativa market, which is forecast to drive over half its peak sales.
• Acknowledge the stock's current 33% valuation premium to peers and assess whether the company's superior growth outlook and drug pipeline optionality sufficiently justify this premium, while monitoring for sector-wide headwinds such as changes in U.S. policy.